Axsome Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Herriot Tabuteau
- Full Time Employees
- 1,346
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- One World Trade Center New York City NY United States of America 10007
- IPO Date
- Nov 19, 2015
- CIK
- 0001579428
- Website
- axsome.com
- Similar Companies
- Business
- Axsome Therapeutics, Inc. stands as a biopharmaceutical firm dedicated to developing innovative treatments for central nervous system (CNS) conditions within the United States. The company’s portfolio features marketed products including Auvelity (dextromethorphan HBr and bupropion HCl extended-release tablets), approved for adults experiencing major depressive disorder, and Sunosi (solriamfetol) for addressing excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Additionally, Symbravo (meloxicam and rizatriptan) recently gained approval in early 2025 for the acute management of migraine with or without aura. Its advanced pipeline continues with AXS-05, currently under an sNDA review with the FDA for Alzheimer's disease agitation, and slated to commence a pivotal Phase 2/3 trial for smoking cessation in late 2025. The company is also progressing AXS-12, a selective norepinephrine reuptake inhibitor, with an NDA submission anticipated in late 2025 for narcolepsy, specifically to treat cataplexy. Another investigational medicine, AXS-14 (esreboxetine), is planned to enter Phase 3 trials for fibromyalgia in late 2025. Further expanding its therapeutic reach, Axsome recently acquired a subtype selective GABA-A receptor positive allosteric modulator for epilepsy in November 2025. The company, established in 2012, maintains its headquarters in New York, New York, focusing on delivering meaningful advancements in patient outcomes.
Company News
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome Begins Phase III Study on AXS-05 for Smoking Cessation
Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation
Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run
BlackRock Inc. Invests $759.70 Million in Axsome Therapeutics, Inc. $AXSM
Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues
Axsome Therapeutics Q2 Earnings Review: I Just Can't See The Value Proposition
Axsome Therapeutics, Inc. (AXSM) Q2 2026 Earnings Call Transcript
Axsome (AXSM) Reports Q2 Earnings: What Key Metrics Have to Say
Axsome Therapeutics (AXSM) Reports Q2 Loss, Misses Revenue Estimates
Axsome Therapeutics Q2 Earnings Call Highlights
Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Axsome Therapeutics (NASDAQ:AXSM) CEO Sells $997,007.00 in Stock
Assenagon Asset Management S.A. Cuts Stock Holdings in Axsome Therapeutics, Inc. $AXSM
Countdown to Axsome (AXSM) Q2 Earnings: Wall Street Forecasts for Key Metrics
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for
New Strong Sell Stocks for July 31st
New Strong Sell Stocks for July 29th
New Strong Sell Stocks for July 27th